- $41.39m
- $148.50m
- $458.51m
Accuray Inc reports results for the quarter ended in September - Earnings Summary
Brief: Accuray Q1 Loss Per Share $0.10
Accuray Inc expected to post a loss of 4 cents a share - Earnings Preview
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:30 AM
Brief: Accuray Sees FY Revenue Between $420 Million And $427 Million
Brief: C-Rad And Accuray Sign Agreement To Enhance Radixact System Breast Cancer Treatment Capabilities
Brief: Accuray Inc and C-Rad Sign Agreement To Enhance Radixact System Breast Cancer Treatment Capabilities
U.S. STOCKS ON THE MOVE-Progenity, Fuelcell, Support.com
U.S. STOCKS ON THE MOVE-PAR Technology, RedHill, Fuelcell Energy
Accuray up after positive follow-up data on cancer treatment system
Brief: Accuray Says Cyberknife Robotic Radiotherapy Platform Is Superior To Conventional Linear Accelerators
Brief: Mika Nishimura Joins Accuray Board Of Directors
Brief: Accuray Posts Q4 Loss Per Share Of $0.12
Accuray Inc reports results for the quarter ended in June - Earnings Summary
Accuray Inc expected to post a loss of 2 cents a share - Earnings Preview
Brief: Accuray Expands Commercialization Of Clearrt™ Helical Fan-Beam Kvct Imaging For The Radixact® System With CE Mark Certification
Brief: Accuray Announces New $120 Million Credit Facility
Accuray Inc reports results for the quarter ended in March - Earnings Summary
Brief: Accuray Reports Q3 EPS $0.00